SCHEMBL1193345

SCHEMBL1193345

O=C(CCl)Nc1ccc(F)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.63
MITF O75030 2/20 0.63
RAB9A P51151 2/20 0.63
GAA P10253 2/20 0.63
XBP1 P17861 1/20 0.63
NPSR1 Q6W5P4 1/20 0.63
NOD2 Q9HC29 1/20 0.63
ALDH1A1 P00352 6/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
HTT P42858 2/20 0.61
PRMT1 Q99873 1/20 0.61
KDM4E B2RXH2 3/20 0.56
KMT2A Q03164 3/20 0.56
MAPT P10636 3/20 0.56
HDAC3 O15379 2/20 0.56
HDAC1 Q13547 2/20 0.56
HDAC2 Q92769 2/20 0.56
HDAC6 Q9UBN7 2/20 0.56
LMNA P02545 2/20 0.56
MEN1 O00255 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9081388 0.89 NPC1 (0.76) NPC1MITFRAB9AXBP1NPSR1
SCHEMBL10919754 0.88 PRMT1 (0.84) NPC1MITFRAB9AGAAXBP1
SCHEMBL11739018 0.86 GAA (0.58) NPC1MITFRAB9AGAAXBP1
SCHEMBL1753925 0.85 GAA (0.70) GAAALDH1A1SMN1; SMN2KDM4EKMT2A
SCHEMBL3317660 0.84 HDAC3 (0.62) RAB9AGAAALDH1A1SMN1; SMN2KDM4E
SCHEMBL15489874 0.82 GAA (0.61) NPC1RAB9AGAAALDH1A1SMN1; SMN2
SCHEMBL16922181 0.81 NPC1 (0.66) NPC1MITFRAB9AGAAXBP1
SCHEMBL6794740 0.81 GAA (0.66) GAAALDH1A1SMN1; SMN2KDM4EKMT2A
SCHEMBL2635734 0.81 NPC1 (0.66) NPC1MITFRAB9AGAAXBP1
SCHEMBL9843748 0.81 GAA (0.66) NPC1RAB9AGAAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220274926-A1 IMMUNOREGULATORY AGENTS FLEXUS BIOSCIENCES INC (US) 2022-09-01 US claimed
CN-113234090-B Compound for targeted ubiquitination degradation of FoxM1 or pharmaceutically acceptable salt thereof, preparation method and application 中国药科大学 2022-07-29 CN claimed
CN-113234090-A Compound for targeted ubiquitination degradation of FoxM1 or pharmaceutically acceptable salt thereof, preparation method and application 中国药科大学 2021-08-10 CN claimed
CN-107400088-B 1, 3-disubstituted pyrazole derivatives, and preparation method and application thereof 山东大学 2020-04-28 CN claimed
CN-102796003-B Preparation method of 2-fluoro-4,5-dichloronitrobenzene UNIV CHANGZHOU 2014-05-28 CN claimed
CN-102796003-A Preparation method of 2-fluoro-4,5-dichloronitrobenzene UNIV CHANGZHOU 2012-11-28 CN claimed
CN-120058445-A Method for generating aryl phenol compound by hydroxylation of uranium photocatalytic aryl fluorine compound and application of method 华东师范大学 2025-05-30 CN disclosed
CN-118496218-A Carbazole-oxadiazole alpha-glucosidase and alpha-amylase double-target inhibitor and preparation method and application thereof 贵州医科大学 2024-08-16 CN disclosed
CN-118146172-A Preparation method of 7-fluoro-6-amino-2H-1, 4-benzoxazine-3 (4H) -one 帕潘纳(北京)科技有限公司 2024-06-07 CN disclosed
US-11932601-B2 Immunoregulatory agents FLEXUS BIOSCIENCES, INC. (US) 2024-03-19 US disclosed
US-20240018135-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF MEDIFRON DBT INC. (KR) 2024-01-18 US disclosed
US-20240018135-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF MEDIFRON DBT INC. (KR) 2024-01-18 US disclosed
US-20240018135-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF MEDIFRON DBT INC. (KR) 2024-01-18 US disclosed
WO-1997040038-A1 PIPERIDINES AND PYRROLIDINES MERCK PATENT GMBH (DE) 1997-10-30 WO disclosed
US-4567264-A ADRENERGIC BLOCKING AGENTS SYNTEX (U.S.A.) INC. (US) 1986-01-28 US disclosed
US-4558129-A Benzodioxanyl-hydroxyethylene-piperazinyl acetanilides which effect calcium entry and β-blockade SYNTEX (U.S.A.) INC. (US) 1985-12-10 US disclosed
US-4499100-A CARDIOUVASCULAR DISORDERS SYNTEX (U.S.A.) INC. (US) 1985-02-12 US disclosed
EP-0126449-A1 Cardioselective aryloxy- and arylthio-hydroxypropyl piperazinyl acetanilides wich affect calcium entry SYNTEX (U.S.A.) INC. (US) 1984-11-28 EP disclosed
US-4017631-A MICROBIOCIDES JANSSEN PHARMACEUTICA N.V. (BE) 1977-04-12 US disclosed
US-3991202-A ANTIMICROBIALS JANSSEN PHARMACEUTICA N.V. (BE) 1976-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932601-B2 Immunoregulatory agents IDO1, IDO2, INMT NPC1 3281/4885MITF 2933/4885RAB9A 3650/4885
US-20220274926-A1 IMMUNOREGULATORY AGENTS IDO1, IDO2, INMT NPC1 3281/4885MITF 2933/4885RAB9A 3650/4885
US-20240018135-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLUSACASE AND USE THEREOF OGA, OGT, ENGASE NPC1 3307/4885MITF 2149/4885RAB9A 2825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.